Neurology

Cerebral adrenoleukodystrophy is a progressive neurodegenerative disease causes irreversible neurologic decline and can result in functional disabilities, such hearing loss and cortical blindness.

A session presenter at the ASCP 2022 Annual Meeting explained how patients’ mismanagement of medications for headaches can lead to rebound headaches.

Eisai plans to file for traditional approval in the United States by March 31, 2023.

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

In patients with hypoxic-ischemic brain injury, researchers observed no significant difference between liberal and restrictive oxygenation on any-cause death.

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Deutetrabenazine is the only VMAT2 inhibitor approved by the FDA for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington disease.

Patients with type 2 diabetes may lower their risk of developing severe neurological disorders like Alzheimer disease by taking certain anti-diabetic medications alongside daily insulin.

Although the treatment of motor symptoms is the primary focus of care for Parkinson disease, helping these patients with sleep disorders is vital because of the impact on quality of life.

New research about the risks of dementia in patients with non-affective psychotic disorders could help shape new life course models for prevention.

New research suggests that psychedelics, and specifically ketamine, can increase neuroplasticity to help a patient with an eating disorder get “unstuck,” and help treat the disorder better than psychotherapy alone.

Antioxidants are capable of converting highly destructive free radicals and nonradical molecules, thereby reducing cerebral stress.

Pharmacists are an essential part of improving care for patients with epilepsy.

Research suggests cannabis can improve quality of life for patients who suffer from pain and neurological disorders.

Establishing new use criteria led to an 86% reduction in the utilization of sugammadex with no appreciable impact on measured outcomes.

Memantine HCl (Namenda) is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.

Investigational targeted B-cell therapy demonstrates superior efficacy compared with teriflunomide, a commonly prescribed treatment for MS.

Ozanimod (Zeposia) is indicated for the treatment of multiple sclerosis and moderately to severely active ulcerative colitis in adults.

Device provides tailored relief to multiple pain areas and adds more treatment options for evolving conditions.

Pregnant women with epilepsy showed more symptoms of anxiety and depression than healthy pregnant or non-pregnant women, but mental health screening may help.

With the help of pharmacists and a team of health care providers, a better quality of life is possible for patients with Parkinson disease.

Researchers find that the risk of developing dementia increased by 35% in patients with atrial cardiopathy.

Seizalam is a benzodiazepine indicated for the treatment of status epilepticus in adults.

As local drug delivery technology evolves, the field is set for monumental change.

Tardive dyskinesia is often caused by the use of dopamine receptor blocking agents, most commonly antipsychotics, for at least a few months.